MCP Launches Generic Division

MCP Pharmaceuticals Launches Generic Division

PARSIPPANY, NJ June 07, 2012 — MCP Pharmaceuticals, a US-based, fully integrated specialty pharmaceutical company, has launched MCP GENERICS.

The launch of MCP GENERICS is the result of MCP’s focus on meeting customer needs for an affordable and reliable supply of high quality products. The generic division will leverage MCP’s established infrastructure in development, manufacturing, marketing and distribution, and will concentrate on the acute care market, which has been challenged by product shortages in recent years.

Stuart Hinchen, President and CEO of MCP Pharmaceuticals commented, “The initial generic portfolio, which are all currently available for purchase, has a range of products in a variety of therapeutic areas including Anesthesiology, Gastroenterology, Infectious Disease and Women’s Healthcare, and totals 13 product SKU’s. Additionally, we have a strong pipeline with several new products launching throughout the course of 2013 and beyond.

These products will contribute toward addressing market shortages in acute care and oncology segments.” The introduction of MCP’s generic division is part of a strategy to expand the business through the establishment of additional growth platforms.

Hinchen added, “MCP already has a very successful arm marketing a range of brand products and a growing Contract Manufacturing business. We continue to actively market our brand name products including Aplisol®, Brevital® and Dantrium®. Further, we have made investments over the past several years to expand capacity in our cGMP-compliant, Rochester Michigan facility, to support growth in MCP labeled products and provide enhanced benefit to our expanding Contract Manufacturing customer base.

We are well poised to support future growth, fueled by a robust pipeline, and look forward to providing an affordable and reliable supply of high quality products through the formation of this new generic division.”

About MCP Pharmaceuticals, LLC MCP Pharmaceuticals, headquartered in New Jersey, is a fully integrated specialty Pharmaceutical company that acquires, develops, manufactures and sells sterile injectable products. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. MCP employs more than 370 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visi



Additional Press Releases



MCP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug
Webpage | PDF Format




MCP Pharmaceuticals Enters Agreement To Produce Life-Saving Drug
Webpage | PDF Format



MCP Pharmaceuticals Launches New Multipack Presentations of Adrenalin®, Coly-Mycin® M and Pitocin®
Webpage | PDF Format



MCP Pharmaceuticals Announces Chief Executive Officer Succession
Webpage | PDF Format



MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format



MCP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format



MCP Pharmaceuticals & Putney Inc. Announce Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format



MCP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement
Webpage | PDF Format



MCP Pharmaceuticals Announces Successful Completion of FDA and EMEA GMP Audits
Webpage | PDF Format



MCP Announces FDA Approval for Dantrium IV, rapidly mixing in 20 seconds
Webpage | PDF Format



MCP Pharmaceuticals & SpePharm complete purchaseof Dantrium® (dantrolene sodium)
Webpage | PDF Format



King Pharmaceuticals Completes Sale Of Rochester, Michigan Manufacturing Facility To MCP Pharmaceuticals
Webpage | PDF Format


Return To Press & News »